Cerus Co. (NASDAQ:CERS) COO Sells $50,998.50 in Stock

Cerus Co. (NASDAQ:CERS) COO Vivek K. Jayaraman sold 33,999 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $1.50, for a total transaction of $50,998.50. Following the completion of the transaction, the chief operating officer now directly owns 1,507,315 shares in the company, valued at approximately $2,260,972.50. This represents a 2.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Cerus Stock Performance

Shares of CERS traded down $0.04 during midday trading on Monday, reaching $1.47. 1,812,528 shares of the stock were exchanged, compared to its average volume of 1,306,882. Cerus Co. has a twelve month low of $1.38 and a twelve month high of $2.54. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The company has a market cap of $273.11 million, a P/E ratio of -13.36 and a beta of 1.56. The stock’s 50 day simple moving average is $1.74 and its 200 day simple moving average is $1.79.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The company had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. On average, sell-side analysts expect that Cerus Co. will post -0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.

Institutional Investors Weigh In On Cerus

Hedge funds and other institutional investors have recently modified their holdings of the company. Rockport Wealth LLC acquired a new stake in shares of Cerus during the fourth quarter worth $25,000. Cibc World Markets Corp bought a new stake in shares of Cerus during the 4th quarter valued at $26,000. R Squared Ltd bought a new stake in shares of Cerus during the 4th quarter valued at $29,000. Virtu Financial LLC bought a new stake in shares of Cerus during the 4th quarter valued at $33,000. Finally, Dark Forest Capital Management LP bought a new stake in shares of Cerus during the 4th quarter valued at $34,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.